MRL Ventures Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 4
- Investments
- 38
- Portfolio
- 13
- Exits
- 16
MRL Ventures Fund General Information
Description
MRL Ventures Fund is a Corporate Venture Capital arm of Merck and Co. based in Cambridge, Massachusetts. The firm seeks to invest in seed and early-stage innovative therapeutics companies by providing long-term and committed capital.
Contact Information
Website
www.mrlv.com
Year Founded
2015
Investor Status
Actively Seeking New Investments
Primary Investor Type
Corporate Venture Capital
Primary Office
- 320 Bent Street
- 4th Floor
- Cambridge, MA 02141
- United States
MRL Ventures Fund Investments (38)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| EyeBio | 24-Feb-2022 | Early Stage VC | 0000 | Biotechnology | Startup | |
| 0000000 0000000000 | 05-Jan-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - General | |
| 0000000 0000000000 | 16-Nov-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 000000 00000000000 | 26-Oct-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
| 000 000000000000 | 15-Jul-2021 | 00000 00000 | 0000 | Drug Discovery | Product Development | |
| 0000000 000 | 10-May-2021 | 0000 00000 | 0000 | Biotechnology | Generating Revenue | 000000000 0000000 00.0 |
| 0000000 0000000000 | 31-Mar-2021 | 00000 00000 | 00000 | Drug Delivery | Pre-Clinical Trials | 000000000 0000000 00.0 |
| 0000000 0000000000 | 01-Mar-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 1 | |
| Xilio Therapeutics | 23-Feb-2021 | Later Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 00000 00000 00.0 |
| LifeMine | 07-Jan-2021 | Early Stage VC | 0000 | Drug Discovery | Startup |
MRL Ventures Fund Exits (16)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Entrada Therapeutics | 02-Nov-2021 | IPO | 00000 |
| 00000 000000000000 | 22-Oct-2021 | 000 | 00000 |
| 000000 00000000000 | 06-Aug-2021 | 000 | 00000 |
| 00000 00000000000 | 09-Jul-2021 | 000 | 00000 |
| 00000 000000000000 | 09-Apr-2021 | 000000000000000000 | 00000 |
| 0000 000000000000 | 25-Mar-2021 | 000 | 00000 |
| 000000 00000000000 | 21-Aug-2020 | 000 | 00000 |
| 0000000 | 30-Jan-2020 | 000000 0000000000 | 00000 |
| Translate Bio | 18-Sep-2019 | Public Investment 2nd Offering | 0000 |
| Alector | 07-Feb-2019 | IPO | 00000 |
MRL Ventures Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialMRL Ventures Fund Team (6)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Peter Dudek Ph.D | Partner | 0 | 0 | 0 | Cambridge, MA |
| Diana Bernstein Ph.D | Senior Associate | Cambridge, MA | |||
| Olga Danilchanka Ph.D | Senior Associate | Cambridge, MA |
MRL Ventures Fund Co-Investors (131)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| AbbVie Ventures | 4 | 0 |
|
|
|
| SV Health Investors | 0 | 0 |
|
|
|
| Amgen Ventures | 0 | 0 |
|
|
|
| GV | 0 | 0 |
|
|
|
| Merck & Co. | 0 | 0 |
|
|